Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer.
PD-1/PD-L1
gynecological malignancy
lncRNAs
miRNAs
ovarian cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Oct 2022
11 Oct 2022
Historique:
received:
24
08
2022
revised:
27
09
2022
accepted:
06
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Ovarian cancer is considered one of the most aggressive and deadliest gynecological malignancies worldwide. Unfortunately, the therapeutic methods that are considered the gold standard at this moment are associated with frequent recurrences. Survival in ovarian cancer is associated with the presence of a high number of intra tumor infiltrating lymphocytes (TILs). Therefore, immunomodulation is considered to have an important role in cancer treatment, and immune checkpoint inhibitors may be useful for restoring T cell-mediated antitumor immunity. However, the data presented in the literature until now are not sufficient to allow for the identification and selection of patients who really respond to immunotherapy among those with ovarian cancer. Although there are some studies with favorable results, more prospective trials are needed in this sense. This review focuses on the current and future perspectives of PD-1/L1 blockade in ovarian cancer and analyzes the most important immune checkpoint inhibitors used, with the aim of achieving optimal clinical outcomes. Future studies and trials are needed to maximize the efficacy of immune checkpoint blockade therapy in ovarian cancer, as well as in all cancers, in general.
Identifiants
pubmed: 36292922
pii: ijms232012067
doi: 10.3390/ijms232012067
pmc: PMC9603705
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Programmed Cell Death 1 Receptor
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Biochem. 2019 Feb 14;:
pubmed: 30767270
Anticancer Res. 2017 Nov;37(11):5955-5965
pubmed: 29061774
Front Immunol. 2020 Sep 10;11:2105
pubmed: 33013886
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Front Oncol. 2021 Apr 16;11:562315
pubmed: 33937012
Diagnostics (Basel). 2020 Mar 07;10(3):
pubmed: 32156035
J Immunol Res. 2015;2015:191832
pubmed: 26236750
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1161-1169
pubmed: 31030490
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Nat Rev Genet. 2014 Jan;15(1):7-21
pubmed: 24296535
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Mod Pathol. 2020 Oct;33(10):2001-2010
pubmed: 32404957
Front Immunol. 2021 Apr 13;12:672502
pubmed: 33927729
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Immunol Rev. 2009 May;229(1):114-25
pubmed: 19426218
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Molecules. 2019 Mar 26;24(6):
pubmed: 30917623
Sci Rep. 2018 Sep 26;8(1):14418
pubmed: 30258080
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Gynecol Oncol Rep. 2019 Jun 18;29:48-54
pubmed: 31312712
Clin Immunol. 2014 Jul;153(1):145-52
pubmed: 24780173
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
J Exp Med. 2001 Apr 2;193(7):839-46
pubmed: 11283156
Trends Immunol. 2001 May;22(5):265-8
pubmed: 11323285
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Front Cell Dev Biol. 2020 Jul 10;8:540
pubmed: 32754587
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
J Gynecol Oncol. 2017 Sep;28(5):e64
pubmed: 28657225
J Ovarian Res. 2019 Apr 30;12(1):37
pubmed: 31039792
Clin Cancer Res. 2013 Mar 15;19(6):1363-74
pubmed: 23340297
Cell Mol Life Sci. 2013 Dec;70(24):4785-94
pubmed: 23880895
Immunity. 2004 Mar;20(3):337-47
pubmed: 15030777
Life Sci. 2019 Aug 15;231:116335
pubmed: 30898647
RNA Biol. 2012 Oct;9(10):1211-7
pubmed: 23047063
Trends Immunol. 2013 Nov;34(11):556-63
pubmed: 23954143
Clin Exp Immunol. 2019 Mar;195(3):334-344
pubmed: 30582756
Front Immunol. 2019 Oct 04;10:2298
pubmed: 31636634
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Annu Rev Pathol. 2009;4:287-313
pubmed: 18842102
Oncotarget. 2015 Aug 7;6(22):18933-44
pubmed: 25895129
Cancer Cell Int. 2017 Nov 17;17:105
pubmed: 29176936
Indian J Med Paediatr Oncol. 2017 Apr-Jun;38(2):182-189
pubmed: 28900328
Oncol Lett. 2018 May;15(5):7200-7206
pubmed: 29755595
Adv Cancer Res. 2019;143:1-62
pubmed: 31202357
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Cancer Immunol Immunother. 2014 Mar;63(3):215-24
pubmed: 24297569
Cancers (Basel). 2020 Nov 16;12(11):
pubmed: 33207823
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208030
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
J Histochem Cytochem. 2012 Jan;60(1):9-21
pubmed: 22205677
Nat Rev Clin Oncol. 2021 Jun;18(6):379-393
pubmed: 33633361
Front Oncol. 2019 Nov 28;9:1292
pubmed: 31850199
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Gynecol Oncol. 2007 May;105(2):404-8
pubmed: 17292461
Lancet Oncol. 2021 Sep;22(9):1275-1289
pubmed: 34363762
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Mol Med Rep. 2015 May;11(5):3647-51
pubmed: 25544258
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Front Immunol. 2019 Aug 09;10:1782
pubmed: 31456796
BMC Med Inform Decis Mak. 2005 Jun 21;5:20
pubmed: 15969765
Womens Health (Lond). 2015 Jun;11(3):355-67
pubmed: 26102473
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Nanomaterials (Basel). 2020 Aug 13;10(8):
pubmed: 32823551
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Cancers (Basel). 2018 Sep 01;10(9):
pubmed: 30200478
Cancers (Basel). 2018 Jul 26;10(8):
pubmed: 30049987
Am J Surg Pathol. 2020 May;44(5):649-656
pubmed: 32294063
Wiad Lek. 2018;71(5):1089-1094
pubmed: 30176647
Pathology. 2013 Apr;45(3):229-42
pubmed: 23478230
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Biochim Biophys Acta. 2014 Nov;1839(11):1097-109
pubmed: 25159663
Adv Immunol. 2006;90:297-339
pubmed: 16730267
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Brief Bioinform. 2022 Jan 17;23(1):
pubmed: 34891154
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Gynecol Oncol. 2018 Dec;151(3):407-413
pubmed: 30366646
Int J Gynecol Pathol. 2008 Apr;27(2):151-60
pubmed: 18317228
Mol Ther. 2022 Apr 6;30(4):1564-1577
pubmed: 35051616
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Anticancer Res. 2018 Oct;38(10):5739-5745
pubmed: 30275195
Cancer. 2019 Dec 15;125 Suppl 24:4616-4622
pubmed: 31967676